This case series aimed to collect preliminary data on the safety and efficacy of treating cats suffering from refractory feline chronic gingivostomatitis with a single intravenous therapy of cryopreserved placenta-derived mesenchymal stromal cells.
The authors planned the prospective inclusion of cats suffering from chronic refractory gingivostomatitis in three veterinary clinics. All cats received a single infusion of 10×106 cryopreserved cells. Follow-up evaluations were done on day 15 and at 2-, 3- and 6 months following infusion. Clinical disease severity was evaluated by dental specialists using a published stomatitis disease activity index scoring system coupled with an owners' assessment questionnaire.
All eight cats attended all follow-up visits. Cryopreserved ready-to-use placenta-derived cells administered systemically were safe and resulted in notable clinical improvement in all cats, as reported by stomatitis disease activity index scoring and owner's survey.
Infusion of cryopreserved freshly thawed placenta-derived mesenchymal stromal cells appears to promote clinical and, consequently, behavioral benefits in cats with chronic refractory gingivostomatitis after having undergone full-mouth or premolar-molar tooth extraction. In conclusion, future randomized studies are required to confirm the safety and efficacy of this treatment.
“Placenta-derived mesenchymal stromal cells as a treatment for refractory chronic gingivostomatitis in cats: eight cases (2018)”. M Febre, et al. J Small Anim Pract. 2022 Dec 26. doi: 10.1111/jsap.13583. https://onlinelibrary.wiley.com/doi/abs/10.1111/jsap.13583